There is evidence for distinct thresholds to govern c-Myc's biological activity in vivo whereby c-Myc's oncogenic activity may arise from its over-expression and interactions with low affinity recognition elements of otherwise c-Myc unregulated genes and by inhibition of tumor suppressor pathways [7]. This evidence concerns the gene MYC and neoplasm.